Muscarinic acetylcholine receptors and airway diseases

Fiona R. Coulson, Allison Fryer

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are due to increased parasympathetic nerve activity. The number and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional. M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity have been demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency. In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma. The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.

Original languageEnglish (US)
Pages (from-to)59-69
Number of pages11
JournalPharmacology and Therapeutics
Volume98
Issue number1
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Muscarinic M2 Receptors
Muscarinic Receptors
Acetylcholine
Bronchoconstriction
Asthma
Mucus
Vitamin A Deficiency
Ozone
Virus Diseases
Vasodilation
Chronic Obstructive Pulmonary Disease
Smooth Muscle Myocytes
Smooth Muscle
Blood Vessels
Animal Models
Antigens

Keywords

  • Airway hyperreactivity
  • Eosinophils
  • Parasympathetic nerves
  • Postjunctional receptors
  • Prejunctional receptors
  • Viruses

ASJC Scopus subject areas

  • Pharmacology

Cite this

Muscarinic acetylcholine receptors and airway diseases. / Coulson, Fiona R.; Fryer, Allison.

In: Pharmacology and Therapeutics, Vol. 98, No. 1, 01.04.2003, p. 59-69.

Research output: Contribution to journalArticle

@article{876ef980dbf84c649cf8a25f7a73120a,
title = "Muscarinic acetylcholine receptors and airway diseases",
abstract = "Parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are due to increased parasympathetic nerve activity. The number and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional. M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity have been demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency. In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma. The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.",
keywords = "Airway hyperreactivity, Eosinophils, Parasympathetic nerves, Postjunctional receptors, Prejunctional receptors, Viruses",
author = "Coulson, {Fiona R.} and Allison Fryer",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0163-7258(03)00004-4",
language = "English (US)",
volume = "98",
pages = "59--69",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Muscarinic acetylcholine receptors and airway diseases

AU - Coulson, Fiona R.

AU - Fryer, Allison

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are due to increased parasympathetic nerve activity. The number and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional. M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity have been demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency. In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma. The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.

AB - Parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are due to increased parasympathetic nerve activity. The number and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. The increase in acetylcholine release occurs because prejunctional, inhibitory M2 muscarinic receptors on the parasympathetic nerves are dysfunctional. M2 muscarinic receptor dysfunction and subsequent airway hyperreactivity have been demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency. In humans, there is evidence that loss of M2 muscarinic receptor function is related to asthma. The mechanisms by which neuronal M2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review.

KW - Airway hyperreactivity

KW - Eosinophils

KW - Parasympathetic nerves

KW - Postjunctional receptors

KW - Prejunctional receptors

KW - Viruses

UR - http://www.scopus.com/inward/record.url?scp=0037377578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037377578&partnerID=8YFLogxK

U2 - 10.1016/S0163-7258(03)00004-4

DO - 10.1016/S0163-7258(03)00004-4

M3 - Article

C2 - 12667888

AN - SCOPUS:0037377578

VL - 98

SP - 59

EP - 69

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -